TrialCancer2012

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Daniel C Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.